Table 1 Patient characteristics
From: Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
Characteristics | p value |
|---|---|
Median age, range (years) | 49(35, 62) |
ECOG status, n (%) | Â |
 0 | 7(18.4) |
 1 | 31(81.6) |
ER status, n (%) | Â |
 Negative | 8(21.1) |
 Positive | 30(78.9) |
PR status, n (%) | Â |
 Negative | 17(44.7) |
 Positive | 21(55.3) |
HER2 status, n (%) | Â |
 Positive | 9(23.7) |
 Negative | 23(60.5) |
 Unknown | 6(15.8) |
Number of prior chemotherapy regimens, n (%) | Â |
 1 | 8(21.1) |
 2 | 17(44.7) |
 3 | 10(26.3) |
 4 | 3(7.9) |
Prior chemotherapy, n (%) | Â |
 Anthracycline + taxanes | 38(100) |
 Capecitabine | 28(73.7) |
 Vinorelbin | 16(42.1) |
 Gemcitabine | 16(42.1) |
Metastatic sites, n (%) | Â |
 Liver | 25(65.8) |
 Lymph nodes | 21(55.3) |
 Lung | 17(44.7) |
 Bone | 14(36.8) |
 Chest wall | 9(23.7) |
 Skin | 1(2.6) |
 Adrenal | 1(2.6) |
Visceral metastasis, n(%) | Â |
 Yes | 5(13.2) |
 No | 33(86.8) |